litlas
ログインアカウント作成

Stan B. Kaye

1989–2022 年に発表

90
論文数
26,812
被引用数
78
h 指数
90
i10 指数

被引用数

Stan B. Kaye の年別被引用数1896 年: 被引用 1 件1991 年: 被引用 4 件1992 年: 被引用 5 件1993 年: 被引用 17 件1994 年: 被引用 14 件1995 年: 被引用 19 件1996 年: 被引用 28 件1997 年: 被引用 19 件1998 年: 被引用 35 件1999 年: 被引用 31 件2000 年: 被引用 39 件2001 年: 被引用 37 件2002 年: 被引用 30 件2003 年: 被引用 71 件2004 年: 被引用 94 件2005 年: 被引用 102 件2006 年: 被引用 112 件2007 年: 被引用 140 件2008 年: 被引用 154 件2009 年: 被引用 217 件2010 年: 被引用 357 件2011 年: 被引用 396 件2012 年: 被引用 381 件2013 年: 被引用 363 件2014 年: 被引用 365 件2015 年: 被引用 352 件2016 年: 被引用 340 件2017 年: 被引用 325 件2018 年: 被引用 265 件2019 年: 被引用 830 件2020 年: 被引用 810 件2021 年: 被引用 695 件2022 年: 被引用 534 件2023 年: 被引用 317 件2024 年: 被引用 467 件2025 年: 被引用 205 件2026 年: 被引用 2 件1897〜1990 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,066 件、この内訳の 27.2%イギリス: 引用元論文 1,160 件、この内訳の 10.3%中国: 引用元論文 1,046 件、この内訳の 9.3%イタリア: 引用元論文 562 件、この内訳の 5%ドイツ: 引用元論文 484 件、この内訳の 4.3%フランス: 引用元論文 463 件、この内訳の 4.1%カナダ: 引用元論文 439 件、この内訳の 3.9%オランダ: 引用元論文 359 件、この内訳の 3.2%スペイン: 引用元論文 337 件、この内訳の 3%オーストラリア: 引用元論文 334 件、この内訳の 2.9%日本: 引用元論文 267 件、この内訳の 2.4%スイス: 引用元論文 211 件、この内訳の 1.9%
0%27.2%その他 22.5%

機関

分野

  • Medicine59.7%
  • Biochemistry, Genetics and Molecular Biology30.7%
  • Materials Science3.1%
  • Immunology and Microbiology1.6%
  • Engineering1%
  • Chemistry0.8%
  • その他3.1%

トピック

  • PARP inhibition in cancer therapy8%
  • Ovarian cancer diagnosis and treatment5.4%
  • DNA Repair Mechanisms4.3%
  • Cancer Genomics and Diagnostics2.7%
  • Prostate Cancer Treatment and Research2.2%
  • BRCA gene mutations in cancer2.2%
  • その他75.2%

共著者

全論文

検索で開く
  1. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

    著者: Peter C.C. Fong, David S. Boss, Timothy A. Yap, Andrew Tutt, Peijun Wu, Marja Mergui‐Roelvink, Peter G. Mortimer, Helen Swaisland, Alan Lau, Mark J. O’Connor, Alan Ashworth, James Carmichael, Stan B. Kaye, Jan H.M. Schellens, Johann S. de Bono - New England Journal of Medicine 2009 被引用: 3,632

  2. A decade of clinical development of PARP inhibitors in perspective

    著者: J. Mateo, Christopher J. Lord, Violeta Serra, Andrew Tutt, Judith Balmañà, Marta Castroviejo‐Bermejo, Cristina Cruz, Ana Oaknin, Stan B. Kaye, Johann S. de Bono - Annals of Oncology 2019 被引用: 730

  3. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research

    著者: Emma Kipps, David S.P. Tan, Stan B. Kaye - Nature reviews. Cancer 2013 被引用: 567

  4. Rethinking ovarian cancer: recommendations for improving outcomes

    著者: Sebastian Vaughan, Jermaine Coward, Robert C. Bast, Andy Berchuck, Jonathan S. Berek, James D. Brenton, George Coukos, Christopher Crum, Ronny Drapkin, Dariush Etemadmoghadam, Michael Friedländer, Hani Gabra, Stan B. Kaye, Christopher J. Lord, Ernst Lengyel, Douglas A. Levine, Iain A. McNeish, Usha Menon, Gordon B. Mills, Kenneth P. Nephew, Amit M. Oza, Anil K. Sood, Euan A. Stronach, Henning Walczak, David D.L. Bowtell, Frances R. Balkwill - Nature reviews. Cancer 2011 被引用: 1,507

  5. Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

    著者: Peter C.C. Fong, Timothy A. Yap, David S. Boss, Craig P. Carden, Marja Mergui‐Roelvink, Charlie Gourley, Jacques De Grève, Jan Lubiński, Susan Shanley, Christina Messiou, Roger A’Hern, Andrew Tutt, Alan Ashworth, John Stone, James Carmichael, Jan H.M. Schellens, Johann S. de Bono, Stan B. Kaye - Journal of Clinical Oncology 2010 被引用: 992

  6. Ovarian cancer: strategies for overcoming resistance to chemotherapy

    著者: Roshan Agarwal, Stan B. Kaye - Nature reviews. Cancer 2003 被引用: 1,179

  7. First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

    著者: Debashis Sarker, Joo Ern Ang, Richard D. Baird, Rebecca Kristeleit, Krunal Shah, Víctor Moreno, Paul A. Clarke, Florence I. Raynaud, Gallia G. Levy, Joseph A. Ware, Kathryn Mazina, Ray Lin, Jenny Wu, Jill Fredrickson, Jill M. Spoerke, Mark R. Lackner, Yibing Yan, Lori S. Friedman, Stan B. Kaye, Mika K. Derynck, Paul Workman, Johann S. de Bono - Clinical Cancer Research 2014 被引用: 360

  8. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

    著者: Johann S. de Bono, Ramesh K. Ramanathan, Lida A. Mina, Rashmi Chugh, John A. Glaspy, Saeed Rafii, Stan B. Kaye, Jasgit C. Sachdev, John V. Heymach, David C. Smith, Joshua W. Henshaw, Ashleigh Herriott, Miranda Patterson, Nicola J. Curtin, Lauren A. Byers, Zev A. Wainberg - Cancer Discovery 2017 被引用: 383

  9. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer

    著者: Michele Moschetta, Angela George, Stan B. Kaye, Susana Banerjee - Annals of Oncology 2016 被引用: 300

  10. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor

    著者: Louise J. Barber, Shahneen Sandhu, Lina Chen, James Campbell, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, Daniel Nava Rodrigues, Jorge S. Reis‐Filho, Víctor Moreno, Joaquı́n Mateo, L Rhoda Molife, Johann S. de Bono, Stan B. Kaye, Christopher J. Lord, Alan Ashworth - The Journal of Pathology 2012 被引用: 335

  11. A radiomics-based decision support tool improves lung cancer diagnosis in combination with the Herder score in large lung nodules

    著者: Benjamin Hunter, Mitchell Chen, Prashanthi Ratnakumar, Esubalew Alemu, Andrew Logan, Kristofer Linton‐Reid, Daniel Tong, Nishanthi Senthivel, Amyn Bhamani, Susannah Bloch, Samuel V. Kemp, Laura Boddy, Sejal Jain, S. Gareeboo, Bhavin Rawal, Simon Doran, Neal Navani, Arjun Nair, Catey Bunce, Stan B. Kaye, Matthew Blackledge, Eric O. Aboagye, Anand Devaraj, Richard W. Lee - EBioMedicine 2022 被引用: 46

  12. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

    著者: Shahneen Sandhu, William R. Schelman, George Wilding, Víctor Moreno, Richard D. Baird, Susana Miranda, Lucy Hylands, Ruth Riisnaes, Martin Förster, Aurelius Omlin, N. Kreischer, Khin Thway, Heidrun Gevensleben, Linda Sun, John W. Loughney, Manash Chatterjee, Carlo Toniatti, Christopher L. Carpenter, Robert Iannone, Stan B. Kaye, Johann S. de Bono, Robert M. Wenham - The Lancet Oncology 2013 被引用: 558

  13. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

    著者: Gerhardt Attard, Alison Reid, Timothy A. Yap, Florence I. Raynaud, Mitch Dowsett, S. Settatree, Mary Barrett, Christopher Parker, Vanessa Martins, Elizabeth Folkerd, Jeremy Clark, Colin S. Cooper, Stan B. Kaye, David P. Dearnaley, Gloria Lee, Johann S. de Bono - Journal of Clinical Oncology 2008 被引用: 896

  14. Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

    著者: Stan B. Kaye, Jan Lubiński, Ursula A. Matulonis, Joo Ern Ang, Charlie Gourley, Beth Y. Karlan, Amnon Amit, Katherine M. Bell‐McGuinn, Lee-may Chen, Michael Friedländer, Tamar Safra, Ignace Vergote, Mark Wickens, Elizabeth Lowe, James Carmichael, Bella Kaufman - Journal of Clinical Oncology 2011 被引用: 474

  15. Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I Trials

    著者: Hendrik‐Tobias Arkenau, Jorge Barriuso, David Olmos, Joo Ern Ang, Johann S. de Bono, Ian Judson, Stan B. Kaye - Journal of Clinical Oncology 2009 被引用: 207

  16. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

    著者: Tim Eisen, T. Ahmad, Keith T. Flaherty, Martin Gore, Stan B. Kaye, Richard Marais, I. Gibbens, Samuel Hackett, Maggie James, Lynn M. Schuchter, Katherine L. Nathanson, Chenjing Xia, Ronit Simantov, Brian Schwartz, Melanie Poulin-Costello, Peter J. O’Dwyer, Mark J. Ratain - British Journal of Cancer 2006 被引用: 636

  17. Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer

    著者: Michał Marek Hoppe, Patrick Jaynes, Joanna D. Wardyn, Sai Srinivas Upadhyayula, Tuan Zea Tan, Stefanus Lie, Diana GZ Lim, Brendan Pang, Sherlly Lim, Joe Yeong, Anthony N. Karnezis, Derek S. Chiu, Samuel Leung, David G. Huntsman, Anna S. Sedukhina, Ko Sato, Monique Topp, Clare L. Scott, Hyungwon Choi, Naina Patel, Robert Brown, Stan B. Kaye, Jason J. Pitt, David S.P. Tan, Anand D. Jeyasekharan - EMBO Molecular Medicine 2021 被引用: 56

  18. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

    著者: Charlotte Benson, Jeff White, Johann S. de Bono, Anne O’Donnell, Florence I. Raynaud, C. Cruickshank, Helen E. McGrath, Michael Walton, Paul Workman, Stan B. Kaye, J Cassidy, Athos Gianella-Borradori, Ian Judson, Chris Twelves - British Journal of Cancer 2006 被引用: 259

  19. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer

    著者: Angela George, Stan B. Kaye, Susana Banerjee - Nature Reviews Clinical Oncology 2016 被引用: 158

  20. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer

    著者: Jennifer McLachlan, Stergios Boussios, Alicia Okines, Daria Glaessgen, S. Bodlar, Ria Kalaitzaki, Allison Taylor, Susan Lalondrelle, Martin Gore, Stan B. Kaye, Susana Banerjee - Clinical Oncology 2016 被引用: 87

  21. Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

    著者: Mark J. Ratain, Tim Eisen, Walter M. Stadler, Keith T. Flaherty, Stan B. Kaye, Gary L. Rosner, Martin Gore, Apurva A. Desai, Amita Patnaik, Henry Q. Xiong, Eric K. Rowinsky, James L. Abbruzzese, Chenghua Xia, Ronit Simantov, Brian Schwartz, Peter J. O’Dwyer - Journal of Clinical Oncology 2006 被引用: 1,030

  22. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

    著者: P. Vasey, Stan B. Kaye, Rachel Morrison, Chris Twelves, Peter D. Wilson, Ruth Duncan, Alison H. Thomson, Lilian S. Murray, T. E. Hilditch, T. Murray, S S Burtles, Daniela Fraier, E. Frigerio, J Cassidy - 1999 被引用: 691

  23. Characterization of ERG , AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

    著者: Gerhardt Attard, Joost F. Swennenhuis, David Olmos, Alison Reid, Elaine Vickers, Roger A’Hern, Rianne Levink, Frank Coumans, J.P.T. Moreira, Ruth Riisnaes, Nikhil Babu Oommen, George Hawche, Charles Jameson, Emilda Thompson, Ronald Sipkema, Craig P. Carden, Christopher Parker, David P. Dearnaley, Stan B. Kaye, Colin S. Cooper, Arturo Molina, Michael Cox, Leon W.M.M. Terstappen, Johann S. de Bono - Cancer Research 2009 被引用: 532

  24. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience

    著者: H-T. Arkenau, David Olmos, Joo Ern Ang, Johann S. de Bono, Ian Judson, Stan B. Kaye - British Journal of Cancer 2008 被引用: 184